Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhertu in HER2-Positive Metastatic Castration-Resistant Prostate Cancer
NCT06610825Phase 2Recruiting
- Sponsor
- Department of Veterans Affairs Medical Centers
- Start
- Mar 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Department of Veterans Affairs Medical Centers. Primary endpoint: Objective Response Rate at 2 years. Started Mar 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06610825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610825.